Clinical trials: neoadjuvant therapy, completed
Locally Advanced Rectal Cancer
Neoadjuvant Triplet Chemotherapy Regimen in Patients With Locally Advanced Rectal Cancer
This study aims to investigate the feasibility, safety and efficacy of triplet regimen of neoadjuvant chemotherapy in patients with locally advanced rectal cancer
- Trial name
- NCT03443661
- Testing
- FOLFOXIRI
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Aiping Zhou
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma
Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This phase I/II trial studies the side effects and the best dose of ruxolitinib phosphate when given together with paclitaxel and carboplatin and to see how well they work in treating patients with stage III-IV epithelial…
- Conditions
- Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, FIGO Stage III Ovarian Cancer 2014
- Trial name
- NCT02713386
- Testing
- Carboplatin, Paclitaxel, Ruxolitinib Phosphate
- Where
- 110 sites in United States
- Volunteers
- 147 people
- Sponsor
- NRG Oncology
HER2 Positive Breast Cancer
Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients.
Pyrotinib is an oral tyrosine kinase inhibitor targeting both HER-1 and HER-2 receptors.This study is a single-arm, prospective, open label clinical study for evaluating the efficacy and safety of neoadjuvant pyrotinib and…
- Trial name
- NCT03735966
- Testing
- Pyrotinib plus trastuzumab and docetaxel and carboplatin
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Henan Cancer Hospital
Bladder Cancer
Neoadjuvant Short-term Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in NMIBC
A randomized controlled trial aiming to investigate neoadjuvant, short-term intensive chemoresection with Mitomycin C compared to standard treatment with TURB and adjuvant intravesical instillation therapy in patients with…
- Trial name
- NICSA (NCT03348969)
- Testing
- Mitomycin c
- Where
- Denmark
- Volunteers
- 120 people
- Sponsor
- Jørgen Bjerggaard Jensen
Contiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma
Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma
This phase II trial is studying how well giving rituximab together with combination chemotherapy and bortezomib works in treating patients with untreated mantle cell lymphoma.
- Conditions
- Contiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Stage I Mantle Cell Lymphoma, Stage III Mantle Cell Lymphoma
- Trial name
- NCT00433537
- Testing
- bortezomib, rituximab, cyclophosphamide
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- National Cancer Institute (NCI)
Rectal Cancer
Surgery Alone Versus Neoadjuvant Treatment Followed by Surgery For MRI-defined T3 Mid-low Rectal Cancer
Neoadjuvant treatments (nCRT) are becoming the standard treatment for patients with stage II or stage III mid-low rectal cancer.
- Trial name
- NCT05496270
- Testing
- total mesorectal excision
- Volunteers
- 1,509 people
- Sponsor
- Sun Yat-sen University
Immunotherapy, Head and Neck Neoplasms
ImmunoModulation by the Combination of Ipilimumab and Nivolumab Neoadjuvant to Surgery In Advanced or Recurrent Head and Neck Carcinoma
This is a phase IB/II trial to examine feasibility and safety of checkpoint blockade (aPD1 with or without aCTLA4) neoadjuvant to standard of care (SOC) in advanced stage head and neck squamous cell carcinoma (HNSCC), a patient…
- Trial name
- IMCISION (NCT03003637)
- Testing
- Nivolumab, Ipilimumab
- Where
- Netherlands
- Volunteers
- 33 people
- Sponsor
- The Netherlands Cancer Institute
Esophageal Cancer, Gastric Cancer
Epirubicin, Oxaliplatin and Fluorouracil (EOF) in Cancer of the Esophagus, Gastroesophageal Junction, or Stomach
RATIONALE: Drugs used in chemotherapy, such as epirubicin, oxaliplatin, fluorouracil, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00601705
- Testing
- cisplatin, epirubicin hydrochloride, fluorouracil
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Case Comprehensive Cancer Center
Immunotherapy Gastrict Cancer, Inflammation Biomarkers
Evaluate the Prognostic Significance of Changes in the Systemic Immune-Inflammation Index in Patients with AGC Treated with ICI Therapy.
The SIIR during neoadjuvant therapy can serve as a specific biomarker for predicting the efficacy of immunotherapy in patients with advanced gastric cancer.
- Conditions
- Immunotherapy Gastrict Cancer, Inflammation Biomarkers, Gastric Cancers
- Trial name
- NCT06706466
- Testing
- observational study
- Where
- China
- Volunteers
- 410 people
- Sponsor
- Chang-Ming Huang, Prof.
Urothelial Carcinoma, Bladder Cancer
Neoadjuvant Toripalimab in Combination With Gemcitabine Therapy in Cisplatin Ineligible Local Advanved Bladder Cancer
This is a pre-surgical study involving subjects with muscle invasive bladder urothelial cancer, who are candidates for cisplatin ineligible neoadjuvant therapy. It is a one-arm phase II study in single center.
- Trial name
- NCT04553939
- Testing
- Toripalimab, Gemcitabine
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Henan Cancer Hospital
Breast Cancer
Genetic Expression and Prediction of Response to Neoadjuvant Docetaxel or Doxorubicin in Locally Advanced Breast Cancer
After a core biopsy of the tumor is obtained, patients with locally advanced breast cancer are randomized to receive 4 cycles of full dose doxorubicin (75 mg/m2 e3w) or docetaxel (100 mg/m2 e3w).
- Trial name
- NCT00123929
- Testing
- docetaxel, doxorubicin
- Where
- Spain
- Volunteers
- 250 people
- Sponsor
- Hospital San Carlos, Madrid
HER2-Positive Early Breast Cancer
A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer
This is a Phase II, randomized, multicentre, multinational, open-label, cross-over study in adult patients who have completed neoadjuvant chemotherapy with neoadjuvant pertuzumab and trastuzumab and have undergone surgical…
- Trial name
- PHranceSCa (NCT03674112)
- Testing
- Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC), Pertuzumab IV, Trastuzumab IV
- Where
- 40 sites in United States, Argentina and 15 more
- Volunteers
- 160 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
Vorinostat in Treating Women With Ductal Carcinoma in Situ of the Breast
RATIONALE: Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This clinical trial is studying how well vorinostat works in treating women with ductal carcinoma in situ…
- Trial name
- NCT00788112
- Testing
- vorinostat, protein expression analysis, immunohistochemistry staining method
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of California, San Francisco
Rectal Cancer
Neoadjuvant Chemoradiation With RHUMAB VEGF (Avastin) for Rectal Cancer
Preoperative chemoradiation leads to increased pelvic control and overall survival, but both distant and local disease control remain problematic in locally advanced rectal cancer patients.
- Trial name
- NCT00113230
- Testing
- Avastin (Bevacizumab, RHUMAB VEGF), Capecitabine, Radiation Therapy
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
HER-2 Positive Breast Cancer
Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast Cancer
The main purpose of this study is to confirm the high pathologic complete response rate after neoadjuvant chemotherapy with FEC followed by weekly paclitaxel and concurrent trastuzumab in Human Epidermal growth factor receptor2…
- Trial name
- NCT01340430
- Testing
- Trastuzumab
- Where
- 6 sites in Italy
- Volunteers
- 43 people
- Sponsor
- Lucia Del Mastro,MD
Breast Cancer
Radiological and Biological Tumoural and Peri-tumoural Factors in Neoadjuvant Endocrine-treated Breast Cancers
The purpose of this study is to monitor the change in cancer size in women with breast cancer on anti-hormone treatment using different types of assessment including ultrasound scan (US), shearwave elastography (SWE) and magnetic…
- Trial name
- BARONET (NCT02701348)
- Testing
- Shearwave elastography, Letrozole, Breast core biopsy
- Where
- United Kingdom
- Volunteers
- 31 people
- Sponsor
- NHS Tayside
Effects of Chemotherapy, Cancer
The Effect of Chemotherapy on Lactate Threshold in Cancer Patients
It is important to assess patients' fitness for major cancer surgery which carries a high risk of mortality. Patients with poor heart and lung function have a higher risk of death after major cancer surgery.
- Trial name
- NCT01335555
- Where
- United Kingdom
- Volunteers
- 89 people
- Sponsor
- Liverpool University Hospitals NHS Foundation Trust
Recurrent Rectal Cancer, Stage IIA Rectal Cancer
Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer
This phase I trial studies the side effects and best dose of trametinib when given together with fluorouracil and radiation therapy before surgery in treating patients with stage II-III rectal cancer.
- Conditions
- Recurrent Rectal Cancer, Stage IIA Rectal Cancer, Stage IIB Rectal Cancer, Stage IIC Rectal Cancer
- Trial name
- NCT01740648
- Testing
- trametinib, fluorouracil, radiation therapy
- Where
- 4 sites in United States
- Volunteers
- 19 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Breast Cancer
PET in Breast Cancer Receiving Neoadjuvant Chemotherapy
Prognostic factors in locally advanced breast cancer treated with neoadjuvant chemotherapy differ from those of early breast cancer.
- Trial name
- DA-PET (NCT01396655)
- Testing
- docetaxel (75 mg/m2) and doxorubicin (50 mg/m2)
- Volunteers
- 78 people
- Sponsor
- Seoul National University Hospital
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8
Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer
This phase I trial studies how well chemokine modulation therapy and standard chemotherapy given before surgery work in treating patients with early stage triple negative breast cancer.
- Conditions
- Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8
- Trial name
- NCT04081389
- Testing
- Celecoxib, Cyclophosphamide, Doxorubicin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Roswell Park Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.